

Jubilant Pharma Australia Pty Ltd
Balance Sheet as at 31 March 2023
(All amounts in AUD, unless otherwise stated)

	Notes	As at 31 March 2023	As at 31 March 2022
ASSETS			
Current assets			
Financial assets			
i. Trade receivables	3	20,486	20,930
ii. Cash and cash equivalents	4	18,880	10,975
Total current assets		39,366	31,905
Total assets		39,366	31,905
EQUITY AND LIABILITIES			
Equity			
Equity share capital	5	20,000	20,000
Other equity		(42,774)	(44,955)
Total equity		(22,774)	(24,955)
Liabilities			
Current liabilities			
Financial liabilities			
i. Trade payables	6	62,140	56,860
Total current liabilities		62,140	56,860
Total liabilities		62,140	56,860
Total equity and liabilities		39,366	31,905

Jubilant Pharma Australia Pty Ltd
Statement of Profit and Loss for the year ended 31 March 2023
(All amounts in AUD, unless otherwise stated)

	Notes	For the year ended 31 March 2023	For the year ended 31 March 2022
Revenue from operations	7	44,710	54,396
Total income		44,710	54,396
Expenses			
Other expenses	8	42,529	46,805
Total expenses		42,529	46,805
Profit before exceptional items and tax		2,181	7,591
Exceptional items		-	-
Profit before tax		2,181	7,591
Total tax expense		-	-
Profit for the year		2,181	7,591
Other comprehensive loss for the year, net of tax		-	-
Total comprehensive income for the year		2,181	7,591

Jubilant Pharma Australia Pty Ltd
Statement of Cash Flows for the year ended 31 March 2023
(All amounts in AUD, unless otherwise stated)

	As at 31 March 2023	As at 31 March 2022
A. Cash flow from operating activities		
Net profit / (loss) before tax	2,181	7,591
Operating cash flow before working capital changes	2,181	7,591
Increase in trade receivables, loans, other financial assets and other assets	444	(49)
Decrease in trade payables, other financial liabilities, other liabilities and provisions	5,280	(2,910)
Cash used in operations	7,905	4,632
Income tax paid (net of refund)		
Net cash used in operating activities	7,905	4,632
B. Cash flow from investing activities		
Net cash generated from investing activities	-	-
C. Cash flow from financing activities		
Net cash generated from financing activities	-	-
Net decrease in cash and cash equivalents (A+B+C)	7,905	4,632
Cash and cash equivalents at the beginning of year	10,975	6,343
Cash and cash equivalents at the end of the year	18,880	10,975

Jubilant Pharma Australia Pty Ltd
Statement of Changes in Equity for the year ended 31 March 2023
(All amounts in AUD, unless otherwise stated)

A. Equity share capital	Amount
Balance as at 1 April 2021	20,000
Changes in equity share capital during the year	-
Balance as at 31 March 2022	20,000
Changes in equity share capital during the year	-
Balance as at 31 March 2023	20,000

B. Other equity

	Reserves and surplus Retained earnings	Total
Balance as at 1 April 2021	(52,546)	(52,546)
Profit for the year	7,591	7,591
Total comprehensive income for the year	7,591	7,591
Balance as at 31 March 2022	(44,955)	(44,955)
Profit for the year	2,181	2,181
Total comprehensive income for the year	2,181	2,181
Balance as at 31 March 2023	(42,774)	(42,774)

Note 1: Corporate information

Jubilant Pharma Australia Pty Ltd ("the Company") is a for-profit proprietary Company, incorporated and domiciled in Australia. The Company is a wholly owned subsidiary of Jubilant Pharma Limited ("the holding company") whose ultimate parent company is Jubilant Pharmova Limited, a company incorporated in India.

The principal activity of Jubilant Pharma Australia Pty Ltd is applying, obtaining and maintaining market authorisation in its name and acting as the importer and distributor of pharmaceuticals products.

Note 2. Significant accounting policies

This note provides a list of the significant accounting policies adopted in the preparation of these financial statements. The accounting policies adopted are consistent with those of the previous financial year.

(a) Basis of preparation

(i) Statement of compliance

These financial statements with limited information have been prepared solely for consideration in the consolidated financial statements of the Ultimate Parent Company. These financial statements have been prepared in accordance with the Ultimate Parent's accounting policies which are in agreement with the recognition and measurement principles laid down under the Companies (Indian Accounting Standards) Rules, 2015, as amended.

(ii) Historical cost convention

These financial statements have been prepared under historical cost convention on accrual basis, unless otherwise stated.

(b) Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency"). The functional currency of the Company is Australian Dollars ("AUD"). These financial statements are presented in AUD.

(c) Current versus non-current classification

The Company presents assets and liabilities in the Balance Sheet based on current/non-current classification.

An asset is treated as current when:

- It is expected to be realised or intended to be sold or consumed in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is expected to be realised within twelve months after the reporting period; or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Company classifies all other assets as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities respectively.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle for the purpose of current-non-current classification of assets and liabilities.

Jubilant Pharma Australia Pty Ltd
Notes to the financial statements for the year ended 31 March 2023
(All amounts in AUD, unless otherwise stated)

Note 5: Equity share capital

	As at	As at
	31 March 2023	31 March 2022
Paid up share capital		
20000 Common stock of no par value	20,000	20,000
	20,000	20,000

Movement in equity share capital	No. of shares	Amount
As at 1 April 2021	20,000	20,000
Additions during the year	-	-
As at 31 March 2022	20,000	20,000
Additions during the year	-	-
As at 31 March 2023	20,000	20,000

Terms and rights attached to equity shares

The Company has only one class of Common stock referred to herein as equity shares. Each holder of common stock is entitled to one vote per common stock. In the event of liquidation of the Company, the stockholders shall be entitled to receive all of the remaining assets of the Company, after distribution of all preferential amounts, if any. Such amounts will be in proportion to the number of common stock of equity shares held by the stockholders.

Details of shareholders holding more than 5% shares in the Company:

	As at		As at	
	31 March 2023		31 March 2022	
	No. of shares	% holding	No. of shares	% holding
Jubilant Pharma Limited - the holding company	20,000	100.00%	20,000	100.00%
Common stock of no par value				

Jubilant Pharma Australia Pty Ltd
Notes to the financial statements for the year ended 31 March 2023
(All amounts in AUD, unless otherwise stated)

Note 3: Trade receivables

	As at	As at
	31 March 2023	31 March 2022
Secured and current		
Trade receivables - considered good	6,600	-
Unsecured and current		
Trade receivables - considered good	13,886	20,930
Total trade receivables	20,486	20,930

Note 4: Cash and cash equivalents

	As at	As at
	31 March 2023	31 March 2022
Balances with banks		
- in current accounts	18,880	10,975
Total cash and cash equivalents	18,880	10,975

Jubilant Pharma Australia Pty Ltd
Notes to the financial statements for the year ended 31 March 2023
(All amounts in AUD, unless otherwise stated)

Note 6: Trade payables

	As at	As at
	31 March 2023	31 March 2022
Current		
Dues to relates parties	43,000	43,000
Dues to others	19,140	13,860
Total trade payables	62,140	56,860

Jubilant Pharma Australia Pty Ltd
Notes to the financial statements for the year ended 31 March 2023
(All amounts in AUD, unless otherwise stated)

Note 7: Revenue from operations

	For the year ended	For the year ended
	31 March 2023	31 March 2022
Sale of products		
Sale of services	44,710	54,396
Total revenue from operations	44,710	54,396

Jubilant Pharma Australia Pty Ltd
Notes to the financial statements for the year ended 31 March 2023
(All amounts in AUD, unless otherwise stated)

Note 8: Other expenses

	For the year ended	For the year ended
	31 March 2023	31 March 2022
Rates and taxes	748	1,995
Payments to statutory auditors	7,040	7,040
Legal and professional fees	32,032	33,665
Bank charges	2,709	4,105
Total other expenses	42,529	46,805